<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390581</url>
  </required_header>
  <id_info>
    <org_study_id>MED-MA-FAS-0628</org_study_id>
    <nct_id>NCT04390581</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands in Participants Age 35 and Older</brief_title>
  <official_title>A Prospective Study Evaluating the Effectiveness of Juvederm Volift With Lidocaine for Treatment of the Aging Hands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of Juvederm Volift with Lidocaine, an injectable gel&#xD;
      implant, to treat aging hands of participants 35 and older.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>At least a 1-point improvement in the Allergan Hand Volume Deficit Scale (AHVDS) by hand from baseline before treatment to 3-month visit.</measure>
    <time_frame>Month 3</time_frame>
    <description>The Evaluating Investigator will grade each hand using the AHVDS 5-point scale where 0= No visible tendons and veins, 1=No protruding tendons, 2=Protruding tendons, 3=Prominent tendons, 4=Tendons very prominent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline to each other post-treatment time points in the Allergan Hand Volume Deficit Scale (AHVDS).</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>The Evaluating Investigator will grade each hand using the AHVDS 5-point scale where 0= No visible tendons and veins, 1=No protruding tendons, 2=Protruding tendons, 3=Prominent tendons, 4=Tendons very prominent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator improvement from baseline to each post-treatment time point using the Global Aesthetic Improvement Scale (GAIS) Investigator</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>The Evaluating Investigator will assess the aesthetic improvement of the hands using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject improvement from baseline to each post-treatment time point using the Global Aesthetic Improvement Scale (GAIS) Subject</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>The Subject will assess the aesthetic improvement of the hands using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and -2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAND-Q Hand Appearance Scale from baseline before treatment to each post-treatment timepoint</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>The Subjects will answer the HAND-Q Hand Appearance Scale questionnaire before injection (baseline) and at each time points after injection. One questionnaire will be completed globally for both hands, taking into account the worst hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin roughness from baseline before treatment to each post-treatment timepoint using PRIMOS ® 3D Lite for skin roughness measurements</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>Measurements of skin microrelief will be performed using PRIMOS ® 3D Lite (Phaseshift Rapid In vivo Measurement Of Skin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin moisture from baseline before treatment to each post-treatment timepoint using MoistureMeter D®</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>MoistureMeter D® (Delfin Technologies) allows to measure water content of biological tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin elasticity from baseline before treatment to each post-treatment timepoint using Cutometer®</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>MPA 580 Cutometer® (Courage &amp; Khazaka) is an in vivo non-invasive method to evaluate skin rheological properties: measures of biological extensibility and elasticity variations. Cutaneous skin elasticity measurement will be performed with a 6mm probe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Site Reactions (ISRs) evaluated by the subject 30 days after each injection using a subject injection site diary.</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing one or more treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>The number of patients who experienced one more TEAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in hand function based on finger goniometer test that will be used to measure any changes in hand function at each post-treatment timepoint.</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>A finger goniometer measures range-of-motion (ROM) of finger joints (metacarpophalangeal and interphalangeal). To measure finger flexion and extension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in hand function based on hand dynamometer test that will be used to measure any changes in hand function at each post-treatment timepoint.</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>A hand dynamometer measures the maximum isometric strength of the hand and forearm muscles. The preferred and non-preferred hand is assessed in an alternating sequence until 3 trials had been completed per hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in hand function based on pinch gauge test that will be used to measure any changes in hand function at each post-treatment timepoint.</measure>
    <time_frame>Day 30, Month 3, Month 6, Month 9, Month 12, Month 15, and Month 18</time_frame>
    <description>A pinch gauge is a hand-held medical device that is used for measuring a patient's hand strength. After the first trial score is recorded, the test is repeated with the same instructions for the second and third trials and for the other hand. The scores of three successive trials for each hand tested is averaged.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Skin Depressions</condition>
  <condition>Skin Elasticity</condition>
  <condition>Skin Laxity</condition>
  <arm_group>
    <arm_group_label>Juvéderm® VOLIFT with Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants to be injected with Juvéderm® VOLIFT with Lidocaine in both hands no more than 6ml total per both hands. Optional touch-up will be done on Day 30 according to aesthetic results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juvéderm® VOLIFT with Lidocaine</intervention_name>
    <description>Consists of one injection of Juvéderm® VOLIFT with Lidocaine to both hands no more than 6ml for both hands total on Day 1. Optional on Day 30.</description>
    <arm_group_label>Juvéderm® VOLIFT with Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Female and male subjects over 35 years of age&#xD;
&#xD;
          -  Has a desire for treatment with hyaluronic acid for skin depressions on both hands&#xD;
&#xD;
          -  Must qualify to receive Juvéderm® VOLIFT®™ with Lidocaine as described in the current&#xD;
             European Union Juvéderm® VOLIFT®™ with Lidocaine Directions For Use (DFU)&#xD;
&#xD;
          -  Accepts the obligation not to receive any other hand cosmetic procedures or treatments&#xD;
             at any time during the study (hand creams are permitted)&#xD;
&#xD;
          -  Agrees not to change their normal hand care regimen throughout the course of the&#xD;
             study.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative urine pregnancy test result at&#xD;
             baseline (Day 1) and practice a reliable method of contraception throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All contraindications as described in the current European Union Juvéderm® VOLIFT®™&#xD;
             with Lidocaine Directions For Use (DFU), as supplied with the product.&#xD;
&#xD;
          -  Receiving or planning to receive anticoagulant therapy during the course of the study,&#xD;
             or received anticoagulant within 10 days prior to study treatment and 3 days after.&#xD;
&#xD;
          -  Receiving or is planning to receive anti-inflammatory drugs (oral/injectable&#xD;
             corticosteroids or NSAIDs, e.g., aspirin, ibuprofen), or other substances known to&#xD;
             increase coagulation time (vitamins or herbal supplements, e.g., Vitamin E, gingko)&#xD;
             for 10 days prior to study treatment and 3 days after&#xD;
&#xD;
          -  Undergone hand surgery, tissue grafting, or tissue augmentation with silicone, fat, or&#xD;
             other permanent, or semi-permanent dermal fillers or be planning to undergo any of&#xD;
             these procedures at any time during the study&#xD;
&#xD;
          -  Undergone temporary hand dermal filler injections with any substance within 12 months&#xD;
             prior to entry in the study&#xD;
&#xD;
          -  Noticeable scarring, active inflammation, infection, cancerous or pre-cancerous&#xD;
             lesion, or unhealed wound or have undergone radiation treatment in the area to be&#xD;
             treated&#xD;
&#xD;
          -  Subject with a dental infection (e.g. infected tooth or paradonitis) or have received&#xD;
             dental cleaning within one month of such infection&#xD;
&#xD;
          -  Subject with history of hypertrophic scarring on hands&#xD;
&#xD;
          -  Any fibrosis or scarring or deformities on the hands - History of neurological disease&#xD;
             that may affect peripheral neurological function&#xD;
&#xD;
          -  Subjects with a history of Raynaud´s disease or phenomenon, or history of other&#xD;
             disease that may affect peripheral circulation&#xD;
&#xD;
          -  Subjects with a history of autoimmune disease or joint disease or connective tissue&#xD;
             disease (e.g., rheumatoid arthritis, lupus, scleroderma etc.)&#xD;
&#xD;
          -  Woman pregnant, lactating, or planning to become pregnant at any time during the study&#xD;
&#xD;
          -  Received any investigational product within 30 days prior to study enrollment or be&#xD;
             planning to participate in another investigation during the course of this study&#xD;
&#xD;
          -  Subject with any skin disease (acute and/or chronic) on the treated zone, likely to&#xD;
             interfere with the measured parameters or to put the subject to an undue risk.&#xD;
&#xD;
          -  Subject with multiple allergies, anaphylactic shock history, evolutive allergic&#xD;
             pathologies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Pharmascan /ID# 233683</name>
      <address>
        <city>Lyon</city>
        <zip>69 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

